Valuation : Evotec

Market Cap 602M 701M 563M 516M 971M 66.92B 974M 6.67B 2.61B 33.73B 2.63B 2.57B 112B P/E 2026 *
-2.88x
P/E 2027 * -7.86x
Enterprise Value 744M 867M 697M 638M 1.2B 82.82B 1.21B 8.25B 3.23B 41.74B 3.26B 3.19B 138B EV / Sales 2026 *
1.24x
EV / Sales 2027 * 1.06x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 59 2024-06-09
Change 5-day change 1-year change 3-year change Capi.($)
-73.86%0.00% - - 701M
-0.29%-0.81%+3.12%+23.53% 51.14B
+2.65%+4.45%+481.36%+567.32% 47.4B
+0.33%+2.47%+38.97%+19.80% 43.19B
-0.88%+0.90%+24.11%+87.74% 42.35B
-2.27%-3.02%+14.22%+51.50% 33.23B
-1.21%-0.17%+29.16%+135.38% 17.07B
-0.36%-2.14% - - 16.38B
-0.33%-0.08%+12.25%+28.50% 14.76B
+0.44%+1.70%+82.07%+47.92% 14.15B
Average -7.57%+0.63%+85.66%+120.21% 31.07B
Weighted average by Cap. -0.23%+1.04%+106.32%+143.52%

Financials

2026 *2027 *
Net sales 600M 699M 561M 514M 968M 66.72B 971M 6.65B 2.6B 33.63B 2.62B 2.57B 111B 719M 838M 673M 617M 1.16B 80.02B 1.16B 7.97B 3.12B 40.33B 3.15B 3.08B 133B
Net income -236M -275M -221M -202M -381M -26.24B -382M -2.61B -1.02B -13.22B -1.03B -1.01B -43.77B -60.37M -70.33M -56.52M -51.76M -97.5M -6.72B -97.77M -669M -262M -3.39B -264M -258M -11.2B
Net Debt 143M 166M 134M 122M 231M 15.89B 231M 1.58B 619M 8.01B 625M 611M 26.51B 162M 189M 152M 139M 262M 18.04B 263M 1.8B 703M 9.09B 709M 694M 30.1B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.384EUR
Average target price
4.586EUR
Spread / Average Target
+35.51%

Quarterly revenue - Rate of surprise